If ur planning on taking a position next week, ya better count some daisies....
The PPS loves me....
....The PPS loves me not....
....The PPS loves me....
.....The PPS loves me not...
I'll spend the day at the spa on the very day we announce SPA.........in case the PPS gets clobbered again on great news......maybe I'll be pleasantly surprised....at least I'll be relaxed....lol.
..... makes ya want to keep that wallet shut tight.
.....if the MC/PPS were metrics of any sort. Amazing. Jeez.
But BP seems to be in search of bolt-on products to quickly bolster not only their pipeline but their bottom line........value they might pay dearly for.
I'm looking forward to a healthy license agreement with either Merck or AZN......one that would leave the shorts without a straw to suck on.
We just need stellar trail results all along the way with the LM science/tech.........breaktrhough designation/accelerated approval would be a big help to get us across the finish line, imo. And like the article said,
“Any additional acquisitions will have to be immediately accretive and will have to be strategically aligned with what we do. And as you can imagine, there aren’t lots of those.”
"......there aren't a lot of those," he said.
To think that our LM science could be ONE of the FEW, is music to my ears....we just have to get to that point, IMO.
Heck, IF we prove that we got the goods, they got the freaking $$$$$$$$$$$$$$, IMO.
Search the title for the complete article (Interesting read and AZN is one of our partners):
"AstraZeneca CEO Raises Bar for Deals After Acquisitions Spree"
AstraZeneca Plc pledged to only pursue acquisitions that immediately add to the drugmaker’s bottom line, following a deal spree in the last quarter of 2015.
“We have what we need to have,” Chief Executive Officer Pascal Soriot told journalists Thursday in London, where the company is based. “Any additional acquisitions will have to be immediately accretive and will have to be strategically aligned with what we do. And as you can imagine, there aren’t lots of those.”
“We’re building we believe formidable franchises, in oncology in particular,” Soriot said. “If you look at oncology three years ago, we had nothing, absolutely nothing. AstraZeneca agreed in November to buy ZS Pharma for $2.7 billion in cash, scooping up a potential blockbuster for a deadly blood condition called hyperkalemia. A month later, the U.K.’s second-biggest drugmaker said it would buy a 55 percent stake in Acerta Pharma BV for $4 billion, gaining access to a potential blockbuster medicine for blood cancer.”
Any additional deals would also have to be in line with AstraZeneca’s strategy of focusing on key disease areas:
Respiratory, inflammation and autoimmunity
Cardiovascular and metabolic diseases
I hope and pray that ADXS cures a big part of these terrible diseases with each and every one of the constructs currently in the pipeline and with all future constructs moving foward.
Search title for article.
No full body condom designs?? (Visions of a life-sized gummy bear....)